Research
Energy balance
Tirzepatide (TZP) caused greater weight loss than placebo (PBO) with a difference of -16.7 kg vs -8.3 kg (p<0.001).
Practitioners can consider TZP as an effective intervention for weight loss in obese patients.
StrongSupportsmedium confidence
TZP caused greater weight loss than PBO (-16.7 kg vs -8.3 kg; p<0.001).
Why this rating
Based on the randomized controlled trial design.
Source
127-OR: The Effect of Tirzepatide during Weight Loss on Metabolic Adaption, Fat Oxidation, and Food Intake in People with Obesity
Éric Ravussin et al. · Diabetes · 2023
rct · n=55Cited 10×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →